VC Veteran Bingham On The Maturation And Future Of British Biotech
Executive Summary
Recently awarded the lifetime achievement award by the BioIndustry Association (BIA), notably for her "enormous contribution to the UK biotech sector during her career", Kate Bingham has time and again proved herself to be a savvy investor in the British biotech industry. She caught up with Jo Shorthouse to discuss what the UK needs to do next to cement its place as Europe's leader in the biosciences.
You may also be interested in...
Brexit: The Implications For Biotech Fundraising And Investment
UK biotech's concerns following the Brexit vote in the EU referendum center around the impact on financing, regulation and personnel, Scrip learns through conversations with a number of industry leaders.
VC Leading $100m Dementia Discovery Fund Reveals New Model
A very early stage fund run by a venture capital firm purely for the discovery of disease-modifying drugs for the treatment of dementia – the Dementia Discovery Fund (DDF) – has been launched. Six pharma companies, the UK government and the charity Alzheimer's Research UK have raised $100m in total in the first closing. It will be run by SV Life Sciences (SVLS), a leading international life sciences VC firm. SVLS's Kate Bingham tells Scrip why she believes the DDF could provide the breakthrough needed to develop new drugs to treat dementia.
Forget IPOs, 'Phenture Capital' exits now controlled by pharma
Venture capital firms no longer see any potential for viable exits through the public markets. Investments by VCs in new companies are now driven on the likelihood of that company being acquired by big pharma and their kind, according to a top venture capitalist. This does not bode well for start-ups with assets that fall outside of traditional pharma wish-lists.